Literature DB >> 33468255

Interstitial lung abnormalities in patients with stage I non-small cell lung cancer are associated with shorter overall survival: the Boston lung cancer study.

Tomoyuki Hida1,2, Akinori Hata3,4, Junwei Lu5, Vladimir I Valtchinov1, Takuya Hino1,2, Mizuki Nishino1,6, Hiroshi Honda2, Noriyuki Tomiyama7, David C Christiani8,9, Hiroto Hatabu1.   

Abstract

BACKGROUND: Interstitial lung abnormalities (ILA) can be detected on computed tomography (CT) in lung cancer patients and have an association with mortality in advanced non-small cell lung cancer (NSCLC) patients. The aim of this study is to demonstrate the significance of ILA for mortality in patients with stage I NSCLC using Boston Lung Cancer Study cohort.
METHODS: Two hundred and thirty-one patients with stage I NSCLC from 2000 to 2011 were investigated in this retrospective study (median age, 69 years; 93 males, 138 females). ILA was scored on baseline CT scans prior to treatment using a 3-point scale (0 = no evidence of ILA, 1 = equivocal for ILA, 2 = ILA) by a sequential reading method. ILA score 2 was considered the presence of ILA. The difference of overall survival (OS) for patients with different ILA scores were tested via log-rank test and multivariate Cox proportional hazards models were used to estimate hazard ratios (HRs) including ILA score, age, sex, smoking status, and treatment as the confounding variables.
RESULTS: ILA was present in 22 out of 231 patients (9.5%) with stage I NSCLC. The presence of ILA was associated with shorter OS (patients with ILA score 2, median 3.85 years [95% confidence interval (CI): 3.36 - not reached (NR)]; patients with ILA score 0 or 1, median 10.16 years [95%CI: 8.65 - NR]; P <  0.0001). In a Cox proportional hazards model, the presence of ILA remained significant for increased risk for death (HR = 2.88, P = 0.005) after adjusting for age, sex, smoking and treatment.
CONCLUSIONS: ILA was detected on CT in 9.5% of patients with stage I NSCLC. The presence of ILA was significantly associated with a shorter OS and could be an imaging marker of shorter survival in stage I NSCLC.

Entities:  

Keywords:  Computed tomography; Interstitial lung abnormality; Lung cancer

Mesh:

Year:  2021        PMID: 33468255      PMCID: PMC7816399          DOI: 10.1186/s40644-021-00383-w

Source DB:  PubMed          Journal:  Cancer Imaging        ISSN: 1470-7330            Impact factor:   3.909


  29 in total

1.  The radiological patterns of interstitial change at an early phase: over a 4-year follow-up.

Authors:  Kenji Tsushima; Shusuke Sone; Sumiko Yoshikawa; Toshiki Yokoyama; Toshiro Suzuki; Keishi Kubo
Journal:  Respir Med       Date:  2010-06-09       Impact factor: 3.415

2.  Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls.

Authors:  Yuzhuo Wang; Olga Y Gorlova; Ivan P Gorlov; Meng Zhu; Juncheng Dai; Demetrius Albanes; Stephen Lam; Adonina Tardon; Chu Chen; Gary E Goodman; Stig E Bojesen; Maria Teresa Landi; Mattias Johansson; Angela Risch; Heunz-Erich Wichmann; Heike Bickeboller; David C Christiani; Gad Rennert; Susanne M Arnold; Paul Brennan; John K Field; Sanjay Shete; Loïc Le Marchand; Olle Melander; Hans Brunnstrom; Geoffrey Liu; Rayjean J Hung; Angeline S Andrew; Lambertus A Kiemeney; Shanbeh Zienolddiny; Kjell Grankvist; Mikael Johansson; Neil E Caporaso; Penella J Woll; Philip Lazarus; Matthew B Schabath; Melinda C Aldrich; Victoria L Stevens; Hongxia Ma; Guangfu Jin; Zhibin Hu; Christopher I Amos; Hongbing Shen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-10       Impact factor: 4.254

3.  Interstitial lung diseases in a lung cancer screening trial.

Authors:  N Sverzellati; L Guerci; G Randi; E Calabrò; C La Vecchia; A Marchianò; A Pesci; M Zompatori; U Pastorino
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

4.  Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.

Authors:  Lynette M Sholl; Dara L Aisner; Marileila Varella-Garcia; Lynne D Berry; Dora Dias-Santagata; Ignacio I Wistuba; Heidi Chen; Junya Fujimoto; Kelly Kugler; Wilbur A Franklin; A John Iafrate; Marc Ladanyi; Mark G Kris; Bruce E Johnson; Paul A Bunn; John D Minna; David J Kwiatkowski
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

5.  Identification of early interstitial lung disease in smokers from the COPDGene Study.

Authors:  George R Washko; David A Lynch; Shin Matsuoka; James C Ross; Shigeaki Umeoka; Alejandro Diaz; Frank C Sciurba; Gary M Hunninghake; Raúl San José Estépar; Edwin K Silverman; Ivan O Rosas; Hiroto Hatabu
Journal:  Acad Radiol       Date:  2009-09-24       Impact factor: 3.173

6.  MUC5B promoter polymorphism and interstitial lung abnormalities.

Authors:  Gary M Hunninghake; Hiroto Hatabu; Yuka Okajima; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Tetsuro Araki; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; Elissa Murphy; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha E Fingerlin; Ivan O Rosas; George R Washko; George T O'Connor; David A Schwartz
Journal:  N Engl J Med       Date:  2013-05-21       Impact factor: 91.245

7.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

8.  Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate.

Authors:  Gong Yong Jin; David Lynch; Ashish Chawla; Kavita Garg; Martin C Tammemagi; Hakan Sahin; Shigeki Misumi; Keun Sang Kwon
Journal:  Radiology       Date:  2013-03-19       Impact factor: 11.105

9.  Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma.

Authors:  Zhaoxi Wang; Yongyue Wei; Ruyang Zhang; Li Su; Stephanie M Gogarten; Geoffrey Liu; Paul Brennan; John K Field; James D McKay; Jolanta Lissowska; Beata Swiatkowska; Vladimir Janout; Ciprian Bolca; Milica Kontic; Ghislaine Scelo; David Zaridze; Cathy C Laurie; Kimberly F Doheny; Elizabeth K Pugh; Beth A Marosy; Kurt N Hetrick; Xiangjun Xiao; Claudio Pikielny; Rayjean J Hung; Christopher I Amos; Xihong Lin; David C Christiani
Journal:  EBioMedicine       Date:  2018-05-31       Impact factor: 8.143

10.  Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.

Authors:  Tetsuro Araki; Suzanne E Dahlberg; Tomoyuki Hida; Christine A Lydon; Michael S Rabin; Hiroto Hatabu; Bruce E Johnson; Mizuki Nishino
Journal:  Eur J Radiol Open       Date:  2019-03-29
View more
  1 in total

1.  Clinical implication of interstitial lung abnormality in elderly patients with early-stage non-small cell lung cancer.

Authors:  Seong Woo Cho; Won Gi Jeong; Jong Eun Lee; In-Jae Oh; Sang Yun Song; Hye Mi Park; Hyo-Jae Lee; Yun-Hyeon Kim
Journal:  Thorac Cancer       Date:  2022-02-11       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.